To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most ...

The global market is estimated at USD 25,900.5 million in 2025 and is forecast to reach USD 64,187.5 million by 2035, ...

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

The "Plant Breeding and CRISPR Plants - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Plant Breeding and CRISPR Plants was valued at US$21 ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The 2025 International Summit on Human Genome Editing called for: • A moratorium on heritable edits until safety and societal consensus are achieved Meanwhile, patients with devastating genetic ...

UCSF’s Program in Craniofacial Biology (PCB) brings together researchers to study the cellular and molecular mechanisms ...

On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...

Institute of Neuroscience, Howard Hughes Medical Institute, University of Oregon, Eugene, United States ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...